Trina Solar Ltd. (TSL)
Shares of TSL surged over 7% in Tuesday’s pre-market trading after the company achieved its second straight quarter of record results and its strongest quarter ever for both upstream and downstream in almost all financial and operating metrics.
For the second quarter 2015, TSL posted revenues of $722.9 million, a 39.2% increase year over year, and net income of $0.42 per diluted American Depository Share (ADS), compared to net income of $0.14 per diluted ADS in the same quarter the prior year, topping the Capital IQ Consensus Estimate of $0.26 earnings per share on revenues of $660.9 million for the period.
TSL said that it is expecting a historically strong year in the global solar market and is confident that it will meet its revised full year module shipment guidance of 4.9 GW to 5.1 GW, which will be over 10% greater than its previous forecast of 4.4 GW to 4.6 GW.
TSL is a global leader in PV modules, solutions and services.
More about Trina Solar Ltd. (TSL) at www.trinasolar.com
Omeros Corp. (OMER)
OMER shares skyrocketed by more than 60% before the opening bell on Tuesday as the company announced additional positive data in its Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs), a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body’s organs, most commonly the kidney and brain.
OMS721 is OMER‘s lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of TMAs, including atypical hemolytic uremic syndrome (aHUS).
Based on clinical data, OMER expects that it can deliver OMS721 either subcutaneously or intravenously at a frequency and dose that are both convenient and comfortable for patients while effectively eliminating lectin-pathway activity.
According to OMER, compassionate use in aHUS patients has begun, and the company looks forward to advancing to the fixed-dose stage of the trial and discussing Phase 3 trial design with the FDA later this year
OMER is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.
More about Omeros Corp. (OMER) at www.omeros.com
Crown Equity Holdings Inc. (CRWE)
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company is currently developing its CRWE WORLD ( www.crweworld.com ), a community targeted platform which goal is to be a one-stop shop for the various needs of online consumers in a range of marketing specialties like Real Estate, Coupons & Deals, Business Directory and more
CRWE WORLD’s business model is based on selling advertising to businesses targeting their marketing message locally, nationally, internationally and also to target potential clients for an specific location, such as within a certain zip code.
CRWE’s Curbiz ( www.curbiz.com ), in development stage, is an online business directory connecting people with local, state, country and global businesses. Curbiz will provide local advertising services, including free and paid business listing services to businesses of various sizes, as well as enable businesses to deliver targeted search advertising to large local audiences through its Website and partnership with the CRWE WORLD Network.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer